HPV Testing And Pap Test Market

Global HPV Testing and Pap Test Market Size (2024 to 2032)

The Global HPV Testing and Pap Test Market size is expected to value USD 4.71 billion in 2024 and is expected to grow at a CAGR of 6.5% during the forecast period and be worth USD 7.79 billion by 2032.

Current Scenario of the HPV Testing and PAP Test Market

The Human Papillomavirus (HPV) test is an analysis to know the presence of human papillomavirus. This HPV leads to cervical cancer or abnormal cervical cells and the development of genital warts. HPV is a virus that transmits sexually, and it is clinically confirmed that HPV is the fundamental cause of cervical cancer. There are two types of cancers which is commonly seen in women: breast cancer and cervical cancer. Cervical cancer is the second most prominent cancer in women. For instance, according to World Health Organisation, cervical cancer is the fourth most common cancer among women. The study says that more than 570,000 new cases were registered in 2018, and it is said that 90% of deaths from cervical cancer occur in emerging and under-developing countries. The Papanicolaou test is a cervical screening procedure for identifying potentially pre-cancerous and cancerous processes in the cervix.

MARKET DRIVERS

The growing aging population, rising number of cervical cancer cases, increasing awareness of cervical cancer screening programs, and government initiatives and funding drive the growth of the HPV testing market.

The rising number of cervical and vaginal cancer cases drives the HPV Testing and Pap Test Market. The growing aging population all around the world and the demand for screening programs are boosting the market. The rising awareness of cervical cancer screening programs is propelling market growth. Moreover, the beneficial policies of the government regarding cardiac monitoring and the rise in the investment or funding in R&D for the development of advanced technology are fueling the market. Moreover, to carry out awareness campaigns, the government and major companies are funding universities to develop enhanced technologies to facilitate effective screening to mitigate the incidence of late-stage cervical cancer.

The rising economy in emerging countries is estimated to grow the HPV Testing and Pap Test Market in the coming years. Moreover, to carry out awareness campaigns, the government and private companies are funding universities to develop enhanced technologies to facilitate effective screening to mitigate the incidence of late-stage cervical cancer, which will boost the market in the future. The aforementioned attribute is setting growth opportunities for the market.

MARKET RESTRAINTS

However, changes in regulatory guidelines for cervical cancer screening and HPV vaccination hinder this market's growth. Additionally, the uncertain reimbursement scenario is a major challenge inhibiting the global HPV testing and PAP test market growth. The changes in the survival guidelines for cervical cancer screening are the primary restraint for the market. The HPV vaccination is stopping the market growth. Moreover, the lack of awareness of pre-cancer screening in emerging countries is the most significant barrier to market growth.

REPORT COVERAGE

Segmental Analysis

HPV Testing and Pap Test Market By Test Type

Based on the test type, the Pap test category is estimated to command the largest share of the HPV testing market in 2023. The HPV testing category is projected to grow at the highest CAGR in the forecast period because of the growing incidences of cervical cancer, raising awareness of HPV screening, and the introduction of HPV primary tests.

HPV Testing and Pap Test Market By Application

Based on the application, the cervical cancer screening application category is estimated to command the largest share of the Pap test market in 2023. This large share is because of the rising incidences of cervical cancer and government initiatives to increase awareness regarding cervical cancer screening benefits.

HPV Testing and Pap Test Market By End-users

Based on end-users, the laboratories' end-user category is likely to command the Pap test market's most significant share in 2023. Moreover, the hospital's end-user category is estimated to grow at the highest CAGR in the future because most of the diagnostic tests are carried out in-house in hospitals using advanced technologies in a relatively shorter period.

Regional Analysis

Geographically, the North American HPV Testing and PAP test market accounted for a significant share of the global market in the regional analysis, which is around 50%. The value of the target market in this region was approximately USD 1.51 billion in 2023. The presence of a high number of cervix cases in the countries like the US and Canada is one of the major factors driving the HPV Testing and Pap Test Market in North America.

The Europe HPV Testing and Pap Test Market were the second-largest in the global market in 2023, which is around 25% and was valued at about USD 1.34 million in 2023. The rising aging population and the growing number of cervical cancer cases are some of the reasons that have augmented the growth of the target market in this region. Also, government initiatives and funding towards this testing in this region's various countries are crucial factors driving the Europe HPV Testing and Pap Test Market.

Whereas Asia-Pacific HPV Testing and Pap Test Market are expected to grow at the highest CAGR during the forecast period. This anticipation is due to the escalating number of cervical cases in APAC. The rising number of hospital construction and growing developments in the early diagnosis of diseases are the other factors pushing the market's growth in the area. Currently, Asia-Pacific HPV Testing and Pap Test Market are valued at around USD 0.99 million in 2023, about 15% of the global market.

KEY MARKET PARTICIPANTS

Some of the notable companies dominating the Global HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.

RECENT HAPPENINGS IN THIS MARKET

• In 2021, QIAGEN N.V., a German provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research, announced the launch of the QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in North America, Europe and other markets globally.
• In 2021, Hologic, Inc., one of the key players of the HPV Testing and Pap Test Market, acquired Diagenode, a privately held European developer and manufacturer of molecular diagnostic assays, for approximately $159 million (130 million euros).

DETAILED SEGMENTATION OF THE GLOBAL HPV TESTING AND PAP TEST MARKET INCLUDED IN THIS REPORT

This research report on the global HPV testing and PAP test market has been segmented and sub-segmented into the following categories.

By Test Type

• HPV Testing
• Follow-up HPV Testing
• HPV Primary Testing
• Co-Testing
• PAP Test

By Application

• Vaginal Cancer Screening
• Cervical Cancer Screening

By End-users

• Laboratories
• Hospitals
• Physicians
• Offices
• Clinics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa